NCT04251091

Brief Summary

This study focuses on investigating exosuit technology by evaluating its ability to provide a gait-restorative effect delivered in both clinic and community settings. The exosuit provides dynamic dorsiflexion and plantarflexion assist during walking. We will determine the effect of training parameters of intensity, repetition, and gait quality which are all key parameters associated with experience-dependent neuroplasticity. The other objective is to determine the effect of this intervention on community walking activity, walking speed, walking distance, and locomotor mechanics and energetics.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for not_applicable stroke

Timeline
Completed

Started Jan 2020

Longer than P75 for not_applicable stroke

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2020

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

January 29, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 31, 2020

Completed
5.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

April 1, 2025

Status Verified

March 1, 2025

Enrollment Period

6 years

First QC Date

January 29, 2020

Last Update Submit

March 31, 2025

Conditions

Keywords

exoskeletonambulationroboticsStrokewalking

Outcome Measures

Primary Outcomes (1)

  • Change in 10 Meter Walk Test from baseline gait speed

    This test will examine the patient's gait speed. Patients will be directed to walk at their preferred and maximum but safe speed. Patients will be positioned 1 meter before the start line and instructed to walk the entire distance and past the end line approximately 1 meter. The distance before and after the course are meant to minimize the effect of acceleration and deceleration. Time will be recorded using a stopwatch and recorded to the one hundredth of a second (ex: 2.15 sec).

    Baseline Day 1-3, Midpoint at week 6, Post-intervention at week 12

Secondary Outcomes (2)

  • Change in 6 Minute Walk Test in distance from baseline

    Baseline Day 1-3, Midpoint at week 6, Post-intervention at week 12

  • Functional Gait Assessment (FGA)

    Baseline Day 1-3, Midpoint at week 6, Post-intervention at week 12

Study Arms (1)

ReWalk Soft Exosuit

EXPERIMENTAL

During this study, we will explore which timing: early timing (10-20%), mid timing (50%) and late timing (90%) may be optimal for an individual and then carry out an 18 session training protocol.

Other: Treadmill walkingOther: Overground Walking

Interventions

Up to 5 bouts of 6 minutes walking on the treadmill with rest breaks allowed between sets

ReWalk Soft Exosuit

Up to 5 bouts of 6 minutes walking overground with rest breaks allowed between sets

ReWalk Soft Exosuit

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 - 80 years old
  • Stroke event occurred at least 6 months ago
  • Observable gait deficits
  • Able to walk without the support of another person for at least 2 minutes (with or without an assistive device or orthotic support)
  • Passive ankle dorsiflexion range of motion to neutral with the knee extended (i.e., able to achieve an angle of 90 degrees between the shank and the foot)
  • Resting heart rate between 40 - 100 bpm, inclusive
  • Resting blood pressure between 90/60 and 170/90 mmHg, inclusive
  • Medical clearance by a physician

You may not qualify if:

  • Score of \>1 on question 1b and \>0 on question 1c on the NIH Stroke Scale
  • Inability to communicate with investigators
  • Neglect or hemianopia
  • Unexplained dizziness in the last 6 months
  • Pressure ulcers or skin wounds located at human-device interface sites
  • History of significant Peripheral Artery Disease (PAD)
  • Unresolved Deep Vein Thrombosis (DVT)
  • Uncontrolled or untreated hypertension
  • Significant paretic ankle contractures (plantarflexion \> 5°)
  • Psychiatric or cognitive impairments that may interfere with proper operation of the device

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shirley Ryan AbilityLab

Chicago, Illinois, 60611, United States

Location

Related Publications (1)

  • Shin SY, Hohl K, Giffhorn M, Awad LN, Walsh CJ, Jayaraman A. Soft robotic exosuit augmented high intensity gait training on stroke survivors: a pilot study. J Neuroeng Rehabil. 2022 Jun 3;19(1):51. doi: 10.1186/s12984-022-01034-2.

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Arun Jayaraman, PT, PhD

    Shirley Ryan AbilityLab

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Previous work has demonstrated that the tuning of the exosuit technology is important for each patient post stroke to be able to maximally utilize the technology. These modulations include when the plantarflexion force is delivered, and how to deliver the assistance within a training session however it is still unclear how to implement this into a training protocol. During a part of this study, we will explore which timing: early timing (10-20%), mid timing (50%) and late timing (90%) may be optimal for an individual and then carry out a training protocol
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 29, 2020

First Posted

January 31, 2020

Study Start

January 10, 2020

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

April 1, 2025

Record last verified: 2025-03

Locations